Brookfield Asset Management enters September under pressure, with a sharp one-week selloff coinciding with a sudden spike in borrowing costs and a cluster of executive share sales that add a note of caution to the picture.
The price move is the starting point. BAM fell 4.9% on the TSX over the past week to C$69.03, with most of that damage coming in a single session — Tuesday saw a 3.3% drop. The selloff is not isolated: parent company BN fell 5.2% on the week, and the broader alternative asset management peer group moved in tandem. Blackstone shed 4.7%, Carlyle fell 4.9%, and ONEX dropped 4.9% over the same period. The sector-wide nature of the move points to macro repricing rather than a BAM-specific catalyst, though the lending market tells a more stock-specific story.
The borrow market has tightened sharply in the past two weeks, and that tension stands out against an otherwise quiet short-interest picture. BAM's cost to borrow hit 4.19% on August 31 — the highest level in the 30-day window and more than triple the 0.49% rate that prevailed through most of August. It has since pulled back to 1.43%, but the spike itself is notable given how stable rates had been. Availability, while still in comfortable territory at around 413% (meaning roughly four shares are available for every one currently borrowed), has tightened materially from levels above 1,000% just a month ago. Short interest itself remains negligible at 0.6% of free float, unchanged week-on-week — so this is not a story about bears rebuilding positions. The CTB spike likely reflects transient demand in the lending pool rather than a structural shift in bearish conviction.
The more telling signal this week is executive selling. CFO Nicholas Goodman sold approximately 12,450 shares on August 21, split across two transactions totalling roughly US$648,000. COO Justin Beber sold a larger block on August 19 — around 31,500 shares for approximately US$1.64 million across two transactions. Both trades carry a low significance score, and none were flagged as 10b5-1 plan sales in the available data, though the clustering of C-suite disposals in a single week is worth noting. Against that, the 90-day net insider position is actually mildly positive at roughly 48,000 shares net bought — driven by director purchases in May and June at prices around C$65-66, below current levels even after this week's pullback.
On valuation and Street positioning, BAM's price-to-earnings ratio has drifted higher over the past month, up roughly 1.6 turns to around 25.3x, while EV/EBITDA has eased marginally to 21.4x. The price-to-book sits at 8.4x — elevated relative to the asset management universe, reflecting the market's historical willingness to pay a premium for Brookfield's fee-generating franchise. The dividend yield factor ranks in the 92nd percentile, a standout strength. Momentum and EPS surprise scores are mid-table, and the short score — at 45, having climbed from 38.6 two weeks ago — is drifting toward neutral rather than signalling any meaningful bearish pressure. No recent analyst rating changes are available in the data to assess current Street direction, so the valuation multiple trajectory is the clearest guide to how investor appetite is shifting.
The dominant institutional holder remains Brookfield Corporation with 74.7% of shares, which keeps the free float narrow and explains why even modest demand shifts can move availability figures significantly. Capital Research added just over three million shares in the most recent reporting period, and RBC Global Asset Management added 1.3 million — incremental buying from credible names. The key watch item into the coming weeks is whether the CTB spike on August 31 was a one-day anomaly or the first indication of more sustained borrow demand, and whether executive selling continues as the stock consolidates after its recent one-month high of roughly C$72.
See the live data behind this article on ORTEX.
Open BAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
